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Objective: Our previous work demonstrated that angiogenesis is inhibited in nonhealing venous ulcers. The object of this
study was to determine whether local expression of vascular endothelial growth factor (VEGF) and other major
regulators of vessel growth are related to healing of venous ulcers.
Subjects and methods: The study included 35 patients with venous ulcers (CEAP 6) and 9 patients whose ulcers had healed
(CEAP 5). Control subjects were 18 patients undergoing routine operations (8 with closed suction drains, 10 standard
skin biopsies). Healing ulcers were defined as having healed in less than a year from entry to the study; nonhealing ulcers
failed to heal in this period. A 1-cm square biopsy specimen was taken from the edge of the ulcer or from a site of
lipodermatosclerosis around a healed ulcer. Wound fluids were aspirated from beneath transparent occlusive dressings.
Concentrations of VEGF165 and VEGF-R1 were measured in tissue homogenates with enzyme-linked immunosorbent
assay, and results are expressed as mean  SEM per milligram of soluble protein (SP). Expression of mRNA transcripts
for the VEGF splice variants VEGF121, VEGF189, and VEGF165; the receptors VEGF-R1 and VEGF-R2; the angiopoi-
etins Ang-1 and Ang-2; and their receptor, Tie-2, were measured in biopsy samples with multiplex polymerase chain
reaction. Expression of each transcript was normalized to that of the housekeeping gene, GAPDH. Results were analyzed
with analysis of variance, t test, and 2 test.
Results: There was no difference in VEGF165 protein concentration between biopsy specimens from healing ulcers (2.12
 0.34 ng/mg SP; n  18) and nonhealing ulcers (2.36  0.39 ng/mg SP; n  12), but concentration was higher in all
ulcer samples compared with healthy skin (0.57  0.20 ng/mg SP; n  10; P < .01)) and healed ulcers (0.33  0.06
ng/mg SP; n  9; P < .01). Concentration of VEGF165 protein in wound fluid was significantly higher in nonhealing
venous ulcers (67.17  13.87 ng/mg SP; n  13) compared with healing venous ulcers (32.19  7.90 ng/mg SP; n 
19; P < .05) or acute wounds (12.26  4.50; n  8; P < .01). Concentration of VEGF-R1 was similar in wound fluid
obtained from healing ulcers (7.18  1.34 ng/mg SP; n  13) and nonhealing ulcers (7.02  1.21 ng/mg SP; n  19),
and acute wounds (7.12  2.35 ng/mg SP; n  8). There was a weak but significant correlation between VEGF165
protein concentration in the ulcer biopsy specimen and wound fluid from the same ulcer (R2  0.2; P  .019; n  27).
Expression of mRNA for VEGF receptors and Tie-2 was poor. VEGF121 was expressed in all samples, and VEGF165 in
43 of 48 samples. mRNA expression of VEGF189 (P .001), Ang-1 (P .002), and Ang-2 (P .026) was found in more
samples from unhealed ulcers than from other sites. Healed ulcers had reduced mRNA expression of VEGF165 (0.181 
0.003) than did healing ulcers (0.307  0.016; P  .007) or nonhealing ulcers (0.375  0.033; P  .001). Relative
expression of VEGF165 to Ang-2 was much lower in healed ulcers (0.4236  0.060) than in healing ulcers (1.382 
0.235; P  .010) and nonhealing ulcers (1.887  0.280; P  .003).
Conclusion: In nonhealing venous ulcers there is a consistently high level of expression of VEGF, at both the gene
transcript and protein level. As our previous data demonstrated that angiogenesis is depressed in these poorly healing
ulcers, an increase in VEGF production may indicate an increased but ineffectual angiogenic drive. It is also possible that
undiscovered inhibitors are released in the ulcer environment. (J Vasc Surg 2003;38:1106-12.)
Venous ulcers are common, with a lifetime prevalence
of 1% to 3% in Western Europe,1-3 and are costly to treat.4
As many as two thirds of venous ulcers heal within 3
months of treatment with compression bandaging,5,6 but
20% persist beyond 1 year and may require excision and skin
grafting. Some venous ulcers never heal despite adequate
treatment, and many of these ulcers have been noted to
have white, avascular, fibrous bases.7
The microcirculation is abnormal in patients with
chronic venous insufficiency, and these changes precede
ulceration. The capillaries are dilated, tortuous, and leaky,
with activated endothelium.8 It has been suggested that
these microcirculatory changes could be linked to increased
production of vascular endothelial growth factor (VEGF).
VEGF is a specific and potent endothelial cell mitogen and
chemotactic agent, and also affects vascular permeability
(VEGF was originally known as vascular permeability fac-
tor).9,10 It is a major regulator of angiogenesis in wound
healing, ischemic revascularization, and tumor growth, and
is produced by a variety of cell types, including macro-
phages, keratinocytes, and endothelial cells.9,11 Immuno-
histochemical studies suggest that there is increased expres-
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sion of VEGF in gaiter skin biopsy specimens in patients
with chronic venous insufficiency,12 and this appears to
correlate with CEAP classification.13 VEGF is also in-
creased in plasma of patients with chronic venous insuffi-
ciency.12
The gene for human VEGF is organized into eight
exons. As a result of alternative splicing, at least four tran-
scripts that encode mature monomeric VEGF are known.
VEGF121 and VEGF165 are diffusible proteins that are
secreted into the medium. VEGF189 and VEGF206 have
high affinity for heparin, and are mostly bound to heparin-
containing proteoglycans in the extracellular matrix.
The VEGF receptors VEGF-R1 and VEGF-R2 are
tyrosine kinases expressed on endothelial cells, which have
an essential role in blood vessel growth.14 VEGF-R2 has
less affinity for VEGF than does VEGF-R1, but is phos-
phorylated 10 times more efficiently on ligand binding.
VEGF-R1 is expressed in two forms via alternate splicing at
the pre-mRNA levels: a full-length membrane-bound re-
ceptor capable of signal transduction, and a truncated
soluble receptor (sVEGF-R1) capable of sequestering li-
gand or dimerizing with the full-length receptor and pre-
venting signal transduction. It is postulated that VEGF-R1
functions to limit VEGF and VEGF-R2 angiogenesis, and
recommended that sVEGF-R1 level be presented along
with VEGF level in experimental and pathologic condi-
tions.15
The angiopoietins, Ang-1 and Ang-2, are also essential
for normal cutaneous wound healing. They bind to another
endothelial cell tyrosine kinase receptor, Tie-2. Ang-2 is
important for breaking down the basement membrane so
that new capillary sprouts can form, whereas Ang-1, its
antagonist, is important in stabilizing new, leaky capillar-
ies.14
We have previously demonstrated that fluid from acute
wounds stimulates angiogenesis, whereas fluid from slow-
healing venous ulcers inhibits angiogenesis and fluid from
rapid-healing venous ulcers has little effect.16 We hypoth-
esized that the environs of a slow-healing venous ulcer may
be deficient in VEGF and that fluid from these wounds may
contain an inhibitor of angiogenesis. We therefore set out
to test this hypothesis by measuring and comparing the
levels of VEGF165 protein and the soluble form of one of its
receptors, VEGF-R1, a putative inhibitor, in samples of
wound fluid and tissue obtained from nonhealing and
healing or healed venous ulcers, acute wounds, lipoderma-
tosclerotic skin, and healthy skin. We also investigated the
relative expression of mRNA for the angiogenic regulators:
VEGF121, VEGF165, and VEGF189; VEGF-R1 and VEGF-
R2; Ang-1 and Ang-2; and Tie-2.
METHODS
Patients. Patients were recruited from the venous leg
ulcer clinic at St Thomas’ Hospital, which is a tertiary
referral center for venous leg ulcers. All patients had a
venous leg ulcer (CEAP 6), that is, an ulcer associated with
varicose veins, venous eczema, lipodermatosclerosis, or ve-
nous reflux at duplex scanning, with no evidence of isch-
emia (ankle-brachial pressure index0.8). Ulcers had been
present for varying duration, and patients had undergone
various treatments before recruitment. Patients were re-
cruited at first attendance at the clinic, when treatment with
three-layer paste or four-layer compression bandaging was
begun. All patients were followed up until the ulcer healed
or for at least 1 year. Ulcers that healed within a year of
treatment were termed “healers,” and those unhealed at 1
year were termed “nonhealers.” Nine patients were re-
cruited after their ulcers had healed (CEAP 5).
Patients undergoing elective surgery were also re-
cruited, to provide samples of healthy skin or acute wound
fluid from closed suction drains.
Ethics approval was granted for the study, and in-
formed patient consent was obtained.
Wound fluid. Wound fluid from 19 healing and 13
nonhealing venous ulcers were collected with the method
described by Trengove et al.17 The ulcers were cleansed,
and covered with an occlusive adhesive dressing (Opsite;
Smith and Nephew Medical, Kingston upon Hull, En-
gland), with use if ether to improve adhesion. After 4 hours
the collected fluid was aspirated from beneath the dressing
with a 5-mL syringe and 21-gauge needle. Acute wound
fluid from eight patients who had undergone mastectomy
was collected from drain bottles on day 2 after the
operation.
All fluid samples were spun at 13,000g for 10 minutes
immediately after collection. The supernatants were snap-
frozen and stored at 80° C until assayed. Supernatants
were diluted 1:10 with phosphate-buffered saline solution
for both VEGF165 and VEGF-R1 analysis.
Biopsy samples. After application of 2% xylocaine lo-
cal anesthetic, 1-cm2 biopsy samples were taken from the
edge of 32 ulcers, with a No. 15 blade scalpel. Eighteen
ulcers subsequently healed; 14 did not heal. Biopsied tissue
was divided into three pieces: base, or granulation tissue
only; edge, or epithelial border; and lipodermatosclerosis,
or intact surrounding skin. Samples were then placed in
labeled cryotubes, snap-frozen in liquid nitrogen, and
stored at 80° C until analysis. Samples from the edge of
the scar from healed venous ulcers (n 9) and from normal
skin obtained at breast reduction (n  10) were also
processed in this manner. All samples were weighed while
still frozen, and a sample approximately 5 to 25 mg was
pulverized with a Microdismembrator II (Braun, Melsun-
gen, Germany) for 60 seconds. The resultant powder was
either dissolved in 1 mL of phosphate-buffered saline solu-
tion for VEGF enzyme-linked immunosorbent assay
(ELISA) or used for mRNA extraction.
ELISA. Concentrations of VEGF and VEGF-R1 were
measured with commercially available sandwich ELISA
(human VEGF165, Duoset; human VEGF-R1, R&D Sys-
tems Europe, UK). All ELISA results were expressed per
milligram of soluble protein (SP).
Protein estimation. Protein concentration of each
sample was measured with the Coomassie brilliant blue G
reaction (DC protein assay system; BioRad, Hercules,
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Calif) against a bovine serum albumin standard (Sigma, St
Louis, Mo).
RNA extraction and RT-PCR. mRNA was extracted
from the pulverized biopsy samples with TRIZOL reagent
(Gibco BRL, Gaithersburg, Md). mRNA from each extract
was then reverse transcribed, and a custom-made multiplex
polymerase chain reaction (PCR) kit (Maxim Biotech) was
used to amplify the following genes: VEGF splice variants
VEGF121, VEGF189, VEGF165 and the receptors VEGF-
R1(flt-1) and R2(flk-1); angiopoietins ang-1 and ang-2 and
their receptor, Tie-2; and GAPDH, which was used as the
housekeeping gene. The primer sequences used in this kit
are given in Table I. PCR was carried out in a total volume
of 25 L. The reaction mix included 2.5 L of 10 buffer,
2 L of 3.12 mmol/L deoxyribonucleoside triphosphate,
2.5 L of 10mPCR primers, 0.5 L of 5U/L Taqman
DNA polymerase (Promega, Madison, Wis), 2.5 L of
cDNA template, and 15 L of DNAase-free water. PCR
reaction conditions were as suggested by the kit instruction
manual: two cycles at 96° C for 1 minute and 58° C for 4
minutes; 35 cycles at 94° C for 1 minute and 58° C for 2.5
minutes, then 70° C for 10 minutes; and hold at 20° C.
Multiplex PCR enabled amplification of multiple genes
from a very small sample. The manufacturer has designed
this kit to give PCR product expression in the exponential
range of amplification.
The PCR product was electrophoresed on 2% agarose
gels containing ethidium bromide. Fluorescent bands were
photographed, digitized, and their presence or absence
recorded. Band density was also measured, with computer-
assisted image analysis (Scion image; National Institutes of
Health, Bethesda, Md). The intensity of bands for all genes
was expressed as ratio to the intensity of the band for the
housekeeping gene, GAPDH.
Statistical analysis. Results were analyzed with analy-
sis of variance (ANOVA), 2 test, and t test, as appropriate.
RESULTS
VEGF165 protein in tissue samples. No difference
was observed in VEGF165 protein concentration in tissue
samples from the edge of healing ulcers (2.12  0.34
ng/mg SP; n  18) compared with biopsy tissue from
nonhealing ulcers (2.36 0.39 ng/mg SP; n 14). Levels
of VEGF were, however, higher in tissue from the edges of
healing ulcers compared with normal skin (0.57  0.20
ng/mg SP; n 10; P	 .01) and lipodermatosclerotic skin
from healed ulcer sites (0.33 0.06 ng/mg SP; n 9; P	
.01; Fig 1).
There was no difference in level of VEGF in tissue from
the ulcer base (1.19  0.28; n  18), ulcer edge (1.47 
0.31 ng/mg SP; n  20), or perilesional lipodermatoscle-
rotic skin (0.89  0.24 ng/mg SP; n  17; Fig 2).
VEGF165 and VEGF-R1 in wound fluid. There was
a weak, but significant, positive correlation between VEGF
concentrations in tissue and wound fluid from the same
ulcer (R2 0.2; n 0.019, Spearman rank correlation; Fig
3). VEGF165 concentration in wound fluid from nonheal-
ing venous ulcers (67.17 13.87 ng/mg SP; n 13) were
significantly higher than in fluid obtained from healing
venous ulcers (32.19  7.90 ng/mg SP; n  13; P 	 .05)
or acute wounds (12.26  4.50; n  8; P 	 .01; Fig 4).
There were no differences in concentrations of soluble
VEGF-R1 in wound fluid obtained from nonhealing (7.02
 1.21 ng/mg SP; n  13) compared with tissue from
healing venous ulcers (7.18 1.34 ng/mg SP; n 19) and
acute wounds (7.12  2.35 ng/mg SP; n  8; Fig 5).
Expression of mRNA angiogenic mediator tran-
scripts. VEGF receptors and Tie-2 were poorly expressed
in all samples. VEGF121 was expressed in all samples, and
VEGF165 was found in 43 of 48 samples. mRNA expression
Fig 1. Vascular endothelial growth factor (VEGF) concentration
in biopsy tissue homogenates. NH, Nonhealing venous ulcers; H,
healing venous ulcers; LDS, previously healed venous ulcers; Skin,
normal skin. Analysis was with ANOVA (P 	 .001), with Tukey
multiple comparison test.
Fig 2. Vascular endothelial growth factor (VEGF) concentration
in biopsy tissue homogenates shows distribution around ulcer.
Analysis with ANOVA.
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of VEGF189 (P  .001), Ang-1 (P  .002), and Ang-2 (P
 .026) were found in more samples from unhealed ulcers
than from other sites (Table II).
Healed ulcers demonstrated lower expression of
VEGF165 (0.181  0.003; n  7) compared with healing
ulcers (0.307  0.016; n  16; P 	 .05) or nonhealing
ulcers (0.375  0.033; n  13; P 	 .01; Fig 6). Relative
expression of VEGF165 to Ang-2 was much lower in healed
ulcers (0.4236  0.060; n  5) than in healing ulcers
(1.382  0.235; n  10; P  .010) or nonhealing ulcers
(1.887  0.280; n  13; P  .003).
DISCUSSION
Approximately 80% of venous ulcers heal with com-
pression treatment within a year, but more than 20% do
not.18 Our previous studies demonstrated that wound fluid
Fig 3. Correlation between vascular endothelial growth factor
(VEGF) concentration (ng/mL soluble protein) in wound fluid
and in biopsy tissue in samples collected simultaneously from same
ulcer (n  27). Analysis was with Spearman rank correlation.
Fig 4. Vascular endothelial growth factor (VEGF) concentration
in fluid from nonhealing venous ulcers (NH), healing venous
ulcers (H), and acute wounds (A). Bars represent mean values.
Analysis was with ANOVA (P  .006), with multiple comparison
test.
Fig 5. Vascular endothelial growth factor receptor-1 (VEGFR1)
concentration in exudates from nonhealing venous ulcers (NH),
healing venous ulcers (H), and acute wounds (A). Bars represent
mean values. No significant difference was observed between any
groups (ANOVA).
Fig 6. Relative intensity of band staining for Vascular endothelial
growth factor165 (VEGF 165) expressed as ratio to band staining for
GAPDH (housekeeping gene). NH, Edge of nonhealing ulcer; H,
edge of healing ulcer; LDS, lipodermatosclerosis at site of previ-
ously healed ulcer. Bars represent mean values. Analysis was with
ANOVA (P  .011), with Tukey multiple comparison test.
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from nonhealing venous ulcers inhibits angiogenesis.16 We
surmise from these previous results that levels of VEGF, the
most potent angiogenic agent, and those of other regula-
tors of angiogenesis (Ang-1, Ang-2, Tie-2) might be de-
pressed in the environs of venous ulcers. We also speculate
that local levels of the VEGF inhibitor, soluble VEGF-R1,
might be increased.
We found that the expression of VEGF165 was in-
creased in tissue and wound fluid from all ulcers, which is at
variance with the results of our angiogenesis assay findings.
VEGF165 protein results were confirmed by equivalent
changes in expression of VEGF165 mRNA. We had ex-
pected depressed levels of VEGF, especially in poorly heal-
ing ulcers, but found the reverse. No corresponding change
was found in the levels of VEGF-R1. Expression of mRNA
for both VEGF-R1 and VEGF-R2 appeared to be more
frequent in nonhealing ulcers compared with all other
tissues. This did not, however, reach statistical significance,
because the overall frequency and level of their expression
were too low for accurate analysis. More detailed studies,
with real-time RT-PCR (Taqman) to accurately quantify
expression of the genes for these growth factors and their
receptors would improve analysis of gene expression in
these tissues.
It is possible that the increased VEGF protein found in
the ulcer microenvironment has come from shed keratino-
cytes at the margins of nonhealing ulcers. Larger ulcers take
longer to heal,19 and wound fluid from these ulcers may
contain a higher concentration of VEGF derived from
increased numbers of detached keratinocytes. Increased
level of VEGF in nonhealing ulcers may simply be a marker
of the degree of inflammation associated with the largest
ulcers.
The excess VEGF that we measured in poorly healing
ulcers may be inactivated by proteolytic degradation, ex-
plaining the reduced angiogenic activity of ulcer exudates.
Western blot analysis has been used by others to measure
changes in VEGF165 after incubation in wound fluid.
20
Results from those studies showed that VEGF is degraded
by ulcer exudate. No comparison was made, however,
between healing and nonhealing venous ulcers. Variable
proteolytic degradation may have been responsible for the
low correlation coefficient between VEGF levels in wound
fluid and paired biopsy specimens. This correlation suggests
that only 20% of VEGF found in wound fluid can be
explained by VEGF found in the biopsy specimen.
Differential expression of spliced variants and VEGF
receptors has been reported in a variety of tissues, including
Table I. Primer sequences used for multiplex polymerase chain reaction
Angiogenic
agent
Band
size
Genbank
number First primer Second primer
VEGF R-1 554 AF063657 GTCATTCCCTGCCGGGTTACGTC CGATGTTTCACAGTGATGAATGCT
Ang-1 472 U83508.1 GATTTCCAAAGAGGCTGGAAGGA TCATCATAGTTGTGGAACGTAAGGAGT
VEGF R-2 408 AF035121 GGCAGCTCACAGTCCTAGAGCGT GGCCCGCTTAACGGTCCGTAG
Tie-2 350 L06139.1 CAGGCAACTTGACTTCGGTGCTAC CACCTGGTATGCTGTTTCAGGCTCT
Ang-2 200 NM_001147.1 ACTCGGTGCAGAGGCTGCAAG CTTCCGCGTTTGCTCAGCTGT
GAPDH 750 M33197 AAGGCTGAGAACGGGAAGCTTG GAGCTTGACAAAGTGGTCGTTGAG
VEGF 189 306 NM03376 CCAGCACATAGGAGAGATGAGCTTC CACCGCCTCGGCTTGTCACAT
VEGF 165 234 AB021221 CCAGCACATAGGAGAGATGAGCTTC CACCGCCTCGGCTTGTCACAT
VEGF 121 104 AF214570 CCAGCACATAGGAGAGATGAGCTTC CACCGCCTCGGCTTGTCACAT
VEGF, Vascular endothelial growth factor; R-1, R-2, receptors 1 and 2; Ang, angiopoietin; Tie-2, angiopoietin receptor; GADPH housekeeping gene.
Table II. mRNA expression of angiogenic mediators in biopsy specimens*
NH
(n  14)
H
(n  17)
LDS
(n  9)
Normal skin
(n  8)
n % n % n % n %
VEGF121 14 100 17 100 9 100 8 100
VEGF165 14 100 16 94 7 78 6 75
VEGF189
† 12 86 6 35 1 11 2 25
VEGF-R1 5 36 1 6 0 0 1 13
VEGF-R2 4 29 1 6 0 0 0 0
Ang-1‡ 11 79 6 35 1 11 1 13
Ang-2§ 11 79 5 29 4 44 2 25
Tie-2 7 50 4 24 1 11 1 13
GAPDH 14 100 17 100 9 100 8 100
NH, Nonhealing venous ulcer (CEAP 6); H, healing venous ulcer (CEAP 6); LDS, lipodermatosclerosis at edge of healed venous ulcer (CEAP 5); n, number
of bands.
*All biopsy specimen taken from edges of lesions.
†P  .001, 2 test.
‡P  .002, 2 test.
§P  .026, 2 test.
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oral mucosa and cartilage.21,22 All splice variants of VEGF
measured (VEGF121, VEGF165, VEGF189) were consis-
tently expressed in ulcer tissue (in nonhealing ulcers, in
particular), and were only sporadically found in lipoderma-
tosclerotic or normal skin. These results suggest that there
is an angiogenic drive in venous ulcers, which appears to be
higher in ulcers with poor healing.
Frequency of expression of the angiopoietins was also
significantly higher in samples from nonhealing ulcers than
from other sites, but their receptor, Tie-2, was poorly
expressed in all tissues. As this system is thought to be
important in formation and stabilization of new blood
vessels, these findings support the concept that angiogen-
esis is poorly facilitated in venous ulcers. The significance of
our results is, however, difficult to interpret, because the
role and interaction of the VEGF splice variants and their
receptors, and the angiopoietins and their receptor in reg-
ulating angiogenesis has yet to be fully defined.
Ours is not the first study to investigate VEGF in
venous disorders. A semiquantitative, immunohistochemi-
cal study compared biopsy samples from healthy limbs with
samples from limbs with venous disorders, lipodermato-
sclerosis, and ulceration. Deeper staining of VEGF was
related to more severe disease (CEAP classification).13 The
level of VEGF in the blood draining the legs of patients
with chronic venous insufficiency has also been correlated
with disease severity, with the highest levels found in the
plasma of patients with ulceration.12
A more recent study compared biopsy specimens from
the edge of venous ulcers with specimens from psoriatic
plaque.20 Concentrations of VEGF mRNA were compara-
ble between the two groups, but immunohistochemical
staining for VEGF protein at the ulcer edge was much
weaker than in the psoriatic tissue. It was suggested that
this apparent discrepancy is the result of proteolytic degra-
dation in ulcers. The concentration of VEGF protein in
ulcer exudates was found to be five times higher than that in
acute wound fluid. These results were, however, expressed
in nanograms per milliliter, and not standardized per gram
weight of soluble protein.
There is controversy over the best method for studying
the microenvironment of venous ulcers.23 It is not practical
to biopsy an entire ulcer, and a biopsy sample provides
information on only one small part of the ulcer at one point
in time. Wound fluid provides information about the global
ulcer environment, but may be contaminated by dead cells
and bacteria. The venous ulcer microenvironment is highly
proteolytic, compared with that of acute wounds. Differ-
ences in results are to be expected, as wound fluid must be
collected over several hours, whereas biopsy specimens can
be frozen immediately.
Soluble VEGF-R1 was one possible inhibitor of angio-
genesis, but increased concentration was not found in
venous ulcer fluid. Angiostatin, formed by fibrinogen deg-
radation,24 and endostatin, produced by collagen degrada-
tion, are two other possible inhibitors produced in a pro-
teolytic environment. Further studies of these inhibitors in
the venous ulcer milieu are indicated.
The results of this study and our previous work (with in
vitro angiogenesis assays) suggest that there is an increased,
but ineffectual, angiogenic drive in nonhealing venous
ulcers. It is possible that an angiogenic inhibitor is present
in increased amounts in the environ of poorly healing
venous ulcers.
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